Inamullah Khan

Dr. Inamullah Khan

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
IKInamullah Khan
Inamullah Khan
MNMuhammad Nisar
Muhammad Nisar
FEFarooq Ebad
Farooq Ebad
SNSaid Nadeem
Said Nadeem
MSMuhammad Saeed
Muhammad Saeed
ZAZia Ahmad
Zia Ahmad

1 October 2011 in Fitoterapia
Verified
Journal Article
Closed access
IKInamullah Khan
Inamullah Khan
MNMuhammad Nisar
Muhammad Nisar
MSMuhammad Raza Shah
Muhammad Raza Shah
HSHamidullah Shah
Hamidullah Shah
SGSyed Naeemuddin Gilani
Syed Naeemuddin Gilani
MUMajeed Ullah
Majeed Ullah

23 September 2011 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
MQMughal Qayum
Mughal Qayum
MNMuhammad Nisar
Muhammad Nisar
MSMuhammad Raza Shah
Muhammad Raza Shah
AAAchyut Adhikari
Achyut Adhikari
WKWaqar Ahmad Kaleem
Waqar Ahmad Kaleem
AKAbad Khan
Abad Khan

1 December 2010 in Fitoterapia
Verified
Journal Article
Closed access
IKInamullah Khan
Inamullah Khan
MNMuhammad Nisar
Muhammad Nisar
NKNematullah Khan
Nematullah Khan
MSMuhammad Saeed
Muhammad Saeed
SNSaid Nadeem
Said Nadeem
IKIhsan Ali Khan
Ihsan Ali Khan

29 June 2015 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MSMuhammad Raza Shah
Muhammad Raza Shah
NINull Ishtiaq
Null Ishtiaq
SHSyed Muhammad Hizbullah
Syed Muhammad Hizbullah
SHSolomon Habtemariam
Solomon Habtemariam
Armando ZarrelliArmando Zarrelli
Armando Zarrelli
IKInamullah Khan
Inamullah Khan
Artemisia roxburghiana is used in traditional medicine for treating various diseases including diabetes. The present study was designed to evaluate the antidiabetic potential of active constituents by using protein tyrosine phosphatase 1B (PTP1B) as a validated target for management of diabetes. Various compounds were isolated as active principles from the crude methanolic extract of aerial parts of A. roxburghiana. All compounds were screened for PTP1B inhibitory activity. Molecular docking simulations were performed to investigate the mechanism behind PTP1B inhibition of the isolated compound and positive control, ursolic acid. Betulinic acid, betulin and taraxeryl acetate were the active PTP1B principles with IC50 values 3.49 ± 0.02, 4.17 ± 0.03 and 87.52 ± 0.03 µM, respectively. Molecular docking studies showed significant molecular interactions of the triterpene inhibitors with Gly220, Cys215, Gly218 and Asp48 inside the active site of PTP1B. The antidiabetic activity of A. roxburghiana could be attributed due to PTP1B inhibition by its triterpene constituents, betulin, betulinic acid and taraxeryl acetate. Computational insights of this study revealed that the C-3 and C-17 positions of the compounds needs extensive optimization for the development of new lead compounds.

10 August 2023 in ACS Omega
Verified
Journal Article
Open access
AAAbid Ali Ahmad
Abid Ali Ahmad
KHKashif Hussain
Kashif Hussain
MSMuhammad Raza Shah
Muhammad Raza Shah
SHSyed Muhammad Ashhad Halimi
Syed Muhammad Ashhad Halimi
FRFazle Rabbi
Fazle Rabbi
HSHafiz Ansar Rasul Suleria
Hafiz Ansar Rasul Suleria
The primary objective of this research was to identifyand explorethe most potent and efficacious cyclooxygenase inhibitors, utilizingindole acetic acid drugs as a lead molecule. To achieve this objective,various derivatives (2a-2c and 2e-2g) of the selected lead molecule, indomethacin, were synthesized usinga reflux condensation process, targeting the hydroxyl group. The synthesizedanalogues were subjected to different spectroscopic procedures todetermine their structure and confirm their analogues. These derivativeswere further screened for acute toxicity and anti-nociceptive andanti-inflammatory activity using established protocols. Docking analysiswas performed to evaluate the possible protein-ligand interaction.The test compounds were found to be safe at doses of 50, 75, 100,and 200 mg/kg, i.p. The pharmacological screening revealed that testcompounds 2a-2f had a superior peripheral analgesiceffect at a dose of 10 mg/kg, in comparison to the parent drug indomethacin,while compound 2g exhibited slightly lower activity atthe same dose. The hot plate results showed lower central analgesicactivity of the test compounds compared to the standard Tramal, butit was still significant. Anti-inflammatory results were significant,comparable to Diclofenac sodium and indomethacin, except for compounds 2b, 2c, and 2e at a dose of 10 mg/kgbody weight. Molecular docking analysis demonstrated that the derivedcompounds had augmented negative binding energies (-149.39,-146.72, -160.85, -159.34, -140.03, and-150.91 KJ/mol) compared to the parent drugs (-141.07),which supported the research's theme of producing strongerderivatives of standard drugs with significant anti-nociceptive andanti-inflammatory potential. The derived compounds exhibited significantanalgesic and anti-inflammatory activities and, therefore, have thepotential to be studied further as new drug candidates for pain andinflammation.